Andres Forero‐Torres
Kirklin Clinic(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Chronic Lymphocytic Leukemia Research, Cancer Treatment and Pharmacology
Most-Cited Works
- → Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma(2012)1,502 cited
- → Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas(2010)1,341 cited
- → Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study(2017)750 cited
- → Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial(2018)710 cited
- → Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer(2020)685 cited
- → TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer(2012)491 cited
- → Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial(2021)308 cited
- → Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study(2008)298 cited
- → Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial(2016)289 cited